Godavari Drugs Ltd

Godavari Drugs maintains a debt-to-equity ratio of 1.48, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is assessed as medium, with a current ratio of 1.08, suggesting limited short-term liquidity cushion. Free cash flow is negative at -131.7 million INR, driven by capital expenditures of -199.98 million INR, which outstrip operating cash flow of 111.96 million INR. Profitability metrics show a return on equity (ROE) of 10.1% and a return on assets (ROA) of 3.06%. These figures are below the typical thresholds for pharmaceutical firms, which often exhibit ROE above 15% and ROA above 5%. The company's net income of 43.8 million INR on revenue of 1.13 billion INR reflects a net margin of 3.86%, which is lower than the median for the industry. The company operates as a single business segment focused on API and intermediates, with all revenue derived from this segment. Geographic exposure is entirely domestic, with no disclosed international operations or revenue diversification. This concentration increases vulnerability to regulatory and macroeconomic shifts in India. Outlook data indicates a projected revenue growth of 8.2% for the current fiscal year, with a 5.1% increase expected in the following year. This growth is driven by increased demand for APIs in the Indian pharmaceutical sector. However, the company's capital expenditures remain a drag on free cash flow, which may constrain reinvestment or dividend capacity. Risk factors include a medium liquidity risk due to the current ratio of 1.08 and a negative net cash position after subtracting total debt. The dilution risk is assessed as low, with no significant dilution sources identified in the latest filings. However, the company's reliance on long-term debt (643.46 million INR) may increase financial leverage in the event of interest rate hikes. Recent events include a 10-K filing disclosing ongoing compliance with Indian pharmaceutical regulations and a Q4 earnings call highlighting the expansion of production capacity at its Nanded facility. No material litigation or regulatory actions were disclosed in the latest reports.